receptor agonists might directly increase NAION risk. That lack of a mechanistic explanation is part of why the FDA refers to the risk as “potential” rather than definitive. At the same time, in a setting where vision loss is involved and signals appear consistently across different types of evidence, regulators often favor caution.

Beyond clinical trials, the FDA turned to its Sentinel Real-World Evidence Data Enterprise to understand how NAION appears in everyday practice. In a retrospective cohort study of adults with type 2 diabetes who started a GLP-1 RA,